Home Newsfeeds Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial

Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial

– ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol – ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023

byBenzinga Newsdesk

July 26, 2022

1 minute read

– ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol

– ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023

News

Markforged Receives Continued Listing Standards Notice From The NYSE

By Happy Mohamed

April 19, 7:14 AM

Markforged Holding Corporation (NYSE:MKFG) ("Markforged" or "the Company"), the company strengthening manufacturing resiliency by enabling industrial production at the point of need, was notified on

MKFG

Cowen & Co. Initiates Coverage On SES AI with Market Perform Rating

By Benzinga Newsdesk

October 31, 8:28 AM

Cowen & Co. analyst Gabe Daoud initiates coverage on SES AI (NYSE:SES) with a Market Perform rating.

SES

Global
News

Princess Cruises Announces Revised 2025 World Cruise Itineraries, Which Will No Longer Visit The Middle East Or Asia, And Now Instead, Will Offer New Port Stops In Africa And Europe Due To Uncertainties In The Red Sea And Surrounding Region

By Benzinga Newsdesk

April 30, 9:34 AM

Uncertainties in the Red Sea and Surrounding Region Prompts Rerouting of Global VoyagesSANTA CLARITA, Calif., April 30, 2024 /PRNewswire/ -- Given the ongoing situation in the Red Sea and surrounding area and

CCL